Theravance Biopharma (NASDAQ: TBPH) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Theravance Biopharma to similar companies based on the strength of its earnings, profitability, institutional ownership, dividends, risk, analyst recommendations and valuation.

Institutional and Insider Ownership

84.5% of Theravance Biopharma shares are held by institutional investors. Comparatively, 43.0% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.1% of Theravance Biopharma shares are held by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Theravance Biopharma and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma 1 0 5 0 2.67
Theravance Biopharma Competitors 849 3762 6786 185 2.54

Theravance Biopharma presently has a consensus target price of $42.67, indicating a potential upside of 47.33%. As a group, “Pharmaceuticals” companies have a potential upside of 23.51%. Given Theravance Biopharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Theravance Biopharma is more favorable than its competitors.

Profitability

This table compares Theravance Biopharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Theravance Biopharma -742.59% -78.74% -43.79%
Theravance Biopharma Competitors -2,886.17% -66.28% -9.23%

Volatility and Risk

Theravance Biopharma has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Theravance Biopharma’s competitors have a beta of 32.19, meaning that their average share price is 3,119% more volatile than the S&P 500.

Earnings and Valuation

This table compares Theravance Biopharma and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Theravance Biopharma $48.65 million -$190.66 million -6.25
Theravance Biopharma Competitors $8.39 billion $1.12 billion 145.99

Theravance Biopharma’s competitors have higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Theravance Biopharma competitors beat Theravance Biopharma on 7 of the 12 factors compared.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.